Screener
Celldex Therapeutics CLDX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -206,220.3%-202,167pp | -35,688.5%-32,815pp | -18,587.7%-15,809pp | -9,855.4%-7,984pp | -4,053.7%-1,936pp | |
| Net margin | -190,220.9%-186,774pp | -32,753.6%-30,388pp | -16,737.2%-14,488pp | -8,635.8%-7,091pp | -3,446.9%-1,637pp | |
| Returns | ||||||
| Return on equity | -43.9%-16.7pp | -48.9%-25.7pp | -40.6%-13.8pp | -32.4%-2.6pp | -27.2%+0.4pp | |
| Return on invested capital | -49.8%-16.5pp | -55.6%-24.9pp | -47%-12.1pp | -38.9%-0.8pp | -33.3%+0.9pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 11.8×-7.8× | 8.9×-12.7× | 10.5×-8.4× | 13×-11.3× | 19.7×-9.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $9.18-7.0% | $6.85-35.3% | $7.94-31.6% | $9.01-24.0% | $9.87-19.9% | |
| Valuation | ||||||
| Market capitalization | $3.26B+129% | $2.11B+75.2% | $1.8B+7.6% | $1.72B-23.8% | $1.44B-41.1% | |
| Price / sales | 20,646.4×+20,401× | 2,438.2×+2,279× | 1,167.4×+929× | 660.7×+435× | 248.2×-45.6× | |
| Price / book | 4.6×+2.4× | 4.6×+2.9× | 3.4×+1.2× | 2.9×0.0× | 2.2×-0.8× |
FAQ
- Where do Celldex Therapeutics's ratios come from?
- Every ratio is computed from Celldex Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
